

## Accepted Manuscript

Antibody fusions with immunomodulatory proteins for cancer therapy

Dafne Müller

PII: S0163-7258(15)00139-4  
DOI: doi: [10.1016/j.pharmthera.2015.07.001](https://doi.org/10.1016/j.pharmthera.2015.07.001)  
Reference: JPT 6798

To appear in: *Pharmacology and Therapeutics*



Please cite this article as: Müller, D., Antibody fusions with immunomodulatory proteins for cancer therapy, *Pharmacology and Therapeutics* (2015), doi: [10.1016/j.pharmthera.2015.07.001](https://doi.org/10.1016/j.pharmthera.2015.07.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

P&T #22830

## **Antibody fusions with immunomodulatory proteins for cancer therapy**

Dafne Müller

Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany

Tel. +49 711 685-66999

Fax. +49 711 685-67484

dafne.mueller@izi.uni-stuttgart.de

### **Abstract**

The potential of immunomodulatory proteins, in particular cytokines, for cancer therapy is well recognized, but hampered by the toxicity associated with their systemic application. In order to address this problem, targeted delivery by antibody fusion proteins has been early proposed and their development intensively pursued over the last decade. Here, factors influencing the selection and modification of cytokines and antibody formats for this approach are being discussed, indicating current developments and translational advances in the field.

### **Abbreviations**

ADCC: antibody-dependent cellular cytotoxicity; AICD: activation-induced cell death; APC: antigen presenting cell; CDC: complement-dependent cytotoxicity; CEA: carcinoembryonic antigen; ED-B: fibronectin extradomain B; ED-A: fibronectin extradomain A; FAP: fibroblast activation protein; FDA: U.S. food and drug administration; NSCLC: non-small cell lung cancer; TnCA1: tenascin C A1 domain.

### **Keywords**

Immunocytokines, antibody-cytokine fusion proteins, targeted cancer immunotherapy

Download English Version:

<https://daneshyari.com/en/article/5843928>

Download Persian Version:

<https://daneshyari.com/article/5843928>

[Daneshyari.com](https://daneshyari.com)